Searchable abstracts of presentations at key conferences in endocrinology

ea0057037 | Euglycemic ketoacidosis in diabetes type 1 | BES2018

Euglycemic ketoacidosis in diabetes type 1

Van den Mooter L , Mathieu C

Background: SGLT2i have shown promising results as an adjunct therapy in T1DM, resulting in better glucose control, weight loss and lower blood pressure. No increase in hypoglycemia risk, in particular severe hypoglycemia, was observed, but, an mild increased risk of (euglycemic) diabetic DKA was reported (Van den Mooter L. et al. Exp Opinion Pharm 2018).Case report: A 49-year-old Caucasian female nurse with underlying type 1 diabetes was admitt...

ea0071004 | Intestinal delivery of proinsulin and IL-10 via Lactococcus lactis combined with low-dose antiCD3 induces antigen-specific FoxP3+ Tregs in autoimmune diabetic mice | BES2020

Intestinal delivery of proinsulin and IL-10 via Lactococcus lactis combined with low-dose antiCD3 induces antigen-specific FoxP3+ Tregs in autoimmune diabetic mice

P-J Martens , G Sassi , M Viaene , J Laureys , L Teyton , P Rottiers , C Gysemans , C Mathieu

Background and aims: An interesting approach in the pursuit for a cure of type 1 diabetes is restoration of immune tolerance by a combination treatment of low-dose aCD3 with the islet antigen proinsulin (PINS) and the pro-tolerogenic cytokine IL-10 administered orally via genetically modified Lactococcus lactis (L. lactis) bacteria. The purpose of adding PINS is to expand antigen-specific Tregs as they are believed to migrate preferentially to disease-related target o...

ea0071012 | Chronic complications versus glycaemic variability, time in range and HbA1c in people with type 1 diabetes: sub study of the RESCUE-trial | BES2020

Chronic complications versus glycaemic variability, time in range and HbA1c in people with type 1 diabetes: sub study of the RESCUE-trial

A El Malahi , M Van Elsen , S Charleer , F De Ridder , K Ledeganck , B Keymeulen , L Crenier , R Radermecker , B Lapauw , C Vercammen , F Nobels , C Mathieu , P Gillard , C De Block

Background and aims: So far, HbA1c is the only metric of glucose control showing a strong association with chronic complications. However, it does not reflect short-term glycemic variability nor provides guidance in decreasing risk of hypoglycemia. More widespread use of continuous glucose monitoring (CGM) has changed the way people with type 1 diabetes (T1D) manage their glycemia by providing information about glycemic variability and time spent in different glucose ranges.</...